Read more about Low Dose Naltrexone
About Us
Discover Immune Therapeutics
Investor data
Read the latest news

LDN (low dose naltrexone)

Low Dose Naltrexone as it is known in the United States, or Lodonal as it is known internationally, has its origins in the FDA approved 50mg Naltrexone. Originally used to treat opiate dependences, the Immune Therapeutics patented treatments, which cover a wide range of indications (link to LDN patents), is currently used as an immune modulator.


OGF/MENK has been shown to halt the growth of the cells and is thought to allow immunological mechanisms (e.g. macrophages, natural killer cells) to accomplish the task of destroying the cancerous cells.

0 8 October 2015

ORLANDO, FL / ACCESSWIRE / October 7, 2015 / Immune Therapeutics Inc. a specialty biopharmaceutical company (IMUN) today provided an update on the ongoing clinical trial of Lodonal in Nigeria.

The trial is an open-label, placebo-controlled study that includes a 90-day treatment period followed by a 60-day extension. The primary objective of this clinical trial is to confirm that Lodonal has a beneficial effect on the immune system of patients in Nigeria with a compromised immune system (refer to Inclusion/Exclusion Criteria). This will be determined by: the number of subjects on Lodonal who achieve CD4 count stabilization (less than 10% change from baseline mean values) or a 25% increase in CD4 counts when compared to the observation group from baseline to Days 30, 60 and 90.

Posted in Press Releases by admin
0 8 October 2015

ORLANDO, FL / ACCESSWIRE / October 7, 2015 / Immune Therapeutics, Inc., a U.S. public company (IMUN), announces the appointment of Saiid Zarrabian as Immune’s newest board member.

Immune is pleased to add Mr. Zarrabian’s 37 years of experience in biotechnology, pharmaceutical, informatics, software and instrumentation/hardware industries to its team. Most recently, Mr. Zarrabian was founding Chairman at La Jolla Pharmaceutical after it was reorganized with new funding, new management team & new products in early 2012. From 2012 to 2013, he was President of the Protein Production Division and Senior Vice President of Intrexon, Inc., a synthetic biology company. From 2010 through 2012, he was President and Chief Executive Officer of Cyntellect, Inc., an instrumentation company with stem cell processing and cell visualization products. Mr. Zarrabian also served as President and Chief Operating Officer of Senomyx, Inc., a public biotechnology company focused on the discovery and commercialization of new flavor ingredients; as Chief Operating Officer of publicly held Pharmacopeia, Inc., a leading provider of combinatorial chemistry discovery services and compounds; as President and Chief Operating Officer of Molecular Simulations, Inc., a company providing software, databases and custom services for the pharmaceutical and chemical industries; and as acting Chief Operating Officer of SciTegic, Inc. until it was acquired by Accelrys, Inc.

Posted in Press Releases by admin
0 12 August 2015

ORLANDO, FL AND DUBLIN, IRELAND / ACCESSWIRE / August 12, 2015 / Immune Therapeutics Inc., a U.S. public company (OTCQB: IMUN) in partnership with GB Pharma Holdings Inc and American Hospitals & Resort [AHAR], today announced that we received approvals from the Nigerian National Agency for Food and Drug Administration and Control [NAFDAC] for the importation of Lodonal(TM).

“We are pleased to receive the import license for Lodonal(TM) in Nigeria,” said Noreen Griffin Immune Therapeutics’ Chief Executive Officer. “This decision further enables the company to pursue Lodonal(TM) approvals in other emerging nations. It is almost impossible to express our thanks for the work of Dr Richards Afonja of AHAR and Dr. Gloria B. Herndon of GB Pharma. Without their continued support, the goal of bringing Lodonal(TM) to Nigeria would not have been possible. The import license is not the final step but an important next step in the process. Full authority to market Lodonal(TM) will be granted upon completion of the clinical trials. The Company hopes to be able to reach an agreement with FIDSON Healthcare Plc., in the coming weeks. We believe this distribution agreement will be key to optimizing the commercialization and launch of Lodonal(TM) making it available to benefit patients suffering from HIV and immune compromised diseases throughout Nigeria.”

Posted in Press Releases by admin
Load More